Jolanda Howe, who serves as senior vice president and global controller at Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), sold 968 shares of the company's common stock on February 2, 2026. The shares were disposed of at a per-share price of $103.3035, producing a gross value of $99997.
The transaction was disclosed in a Form 4 filing with the Securities and Exchange Commission, which states the sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units. The Form 4 also records that Howe exercised options on 1,771 shares of Mirum common stock on January 31, 2026.
Separately from the insider transaction, Mirum released preliminary unaudited net product sales figures for 2025, reporting approximately $520 million in net product revenue for the year. That result exceeded the company's earlier guidance. For 2026, Mirum projected global net product sales in a range between $630 million and $650 million, an increase that the company characterized as reflecting potential growth of up to 25% year-over-year.
In a related corporate development, Mirum completed its acquisition of Bluejay Therapeutics. The purchase brings brelovitug, a late-stage investigational treatment for chronic hepatitis delta virus, into Mirum's portfolio. According to company disclosures, brelovitug is being evaluated in a global Phase 3 trial, with topline results anticipated in the second half of 2026.
Analysts have reacted to Mirum's recent commercial and corporate milestones with several updates to coverage and price targets. H.C. Wainwright raised its price target to $130 and maintained a Buy rating, citing the potential of Mirum's drug candidate volixibat. Citizens reiterated a Market Outperform rating and a $140 price target, pointing to the company's robust 2025 sales and ongoing growth trajectory. Baird also increased its price target to $95 and kept an Outperform rating, noting strong sales results for 2025 as the basis for its view.
This combination of insider activity, updated sales figures, forward-looking revenue guidance, an acquisition adding a late-stage asset, and fresh analyst price targets provides multiple discrete data points for investors and market participants to consider when assessing Mirum's near-term outlook.
Summary: Jolanda Howe sold 968 Mirum shares on February 2, 2026, at $103.3035 per share to cover tax withholding from RSU vesting; she had exercised options on 1,771 shares on January 31, 2026. Mirum reported preliminary unaudited 2025 net product sales of about $520 million, issued 2026 sales guidance of $630 million to $650 million, completed the Bluejay Therapeutics acquisition adding brelovitug, and drew analyst target increases from H.C. Wainwright, Citizens, and Baird.
Key points:
- Insider transaction - Jolanda Howe sold 968 shares on February 2, 2026, for $99997 to satisfy tax withholding tied to RSU vesting.
- Operational results and outlook - Mirum reported approximately $520 million in preliminary unaudited net product sales for 2025 and guided $630 million to $650 million for 2026.
- Portfolio and analyst developments - Mirum closed the Bluejay acquisition adding brelovitug (Phase 3, results expected H2 2026) and saw multiple analyst price-target increases and reiterated bullish ratings.
Risks and uncertainties:
- Clinical trial timing - The Phase 3 trial for brelovitug is ongoing with results expected in the second half of 2026; timing and outcome remain uncertain.
- Guidance reliance - The 2026 projection of $630 million to $650 million in net product sales is a company outlook and may be subject to change as the year progresses.
- Insider sales context - The sale by a senior officer was recorded as tax-withholding related; investors may interpret insider transactions differently, and the sale does not by itself indicate broader executive intent.